

***iLite*[®] Diluent D**

(REF: BM3250)

- Description** *iLite*[®] Diluent D can be used in *iLite*[®] Type I IFN bioassays.
- Content** 20 mL of *iLite* Diluent D containing RPMI 1640 with 1% heat inactivated fetal bovine serum (FBS) and 1% Penicillin Streptomycin.
- Receipt and storage** Upon receipt confirm that adequate dry-ice is present and that the reagent is frozen. Immediately transfer to -80°C storage (**do not store at any other temperature**).
- Background** Interferon alpha (IFN α) has been widely used to treat chronic viral hepatitis and a wide variety of malignant diseases, including hairy cell leukemia, basal cell carcinoma, chronic myeloid leukemia and cutaneous T-cell lymphoma. Several different recombinant preparations of IFN α are available commercially; the most commonly used formulations include IFN α 2a and IFN α 2b. A number of studies have shown that development of anti-IFN α neutralizing antibodies (NAbs) is correlated with a loss of IFN α treatment efficacy.
- Interferon beta (IFN β) is well established as first line therapy in relapsing/remitting multiple sclerosis. The occurrence of NAbs and binding antibodies (BAbs) to IFN β has been widely reported. Subjects with NAbs have shown reduced response to treatment with IFN β , having higher relapse rates, increased MRI activity and higher risk of disease progression. The frequencies and titers of NAbs vary depending on the preparation used, dose and frequency of administration and also the assay used to quantify them.
- Application** The *iLite*[®] Diluent D may be used in both the Type I IFN drug level assay and in the measurement of anti-IFN α or β antibodies (NAbs).
- Application Notes for the following assays are available:
- Quantification of IFN α or β (E-176-GB)
 - Measurement of anti-IFN α or β antibodies (NAbs) (E-175-GB)

Related products

REF	Product name
BM3049	<i>iLite</i> [®] Type I IFN Assay Ready Cells
BM3249	<i>iLite</i> [®] IFN beta 1a (950 IU/mL)
BM3251	<i>iLite</i> [®] IFN beta 1a NAb positive control

References

Hermanrud C, Ryner M, Luft T, Jensen PE, Ingenhoven K, Rat D, Deisenhammer F, Sørensen PS, Pallardy M, Sikkema D, Bertotti E, Kramer D, Creeke P, Fogdell-Hahn A, on behalf of the ABIRISK consortium: Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta. J Immunol Methods 430: 1-9 (2016).



Symbols on label

	Lot number		Temperature limitation
	Catalogue number		Biohazard
	Use by		Manufacturer

Precautions

- For research use only. This product is intended for professional laboratory research use only. The data and results originating from using the product should not be used either in diagnostic procedures or in human therapeutic applications.

- The product contains human/bovine serum and if human serum is analysed it should be handled as if capable of transmitting infectious agents.

- Residues of chemicals and preparations are generally considered as biohazardous waste, and should be inactivated prior to disposal by autoclaving or using bleach. All such materials should be disposed of in accordance with established safety procedures.

Propriety information

In accepting delivery of *iLite* Assay Ready Cells the recipient agrees not to sub-culture these cells, attempt to sub-culture them or to give them to a third party, and only to use them directly in assays. Biomonitor *iLite* cell-based products are covered by patents which are the property of Euro Diagnostica AB and any attempt to reproduce the delivered *iLite* Assay Ready Cells is an infringement of these patents.